SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

Home・Aktien・Nanobiotix

N
Nanobiotix

Geschlossen

25.54 0.95

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

26.8

Schlüsselkennzahlen
By Trading Economics
Einkommen	-5.4M
Verkäufe	27M
Gewinnspanne	-20.208
Angestellte	103
EBITDA	1.1M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+24.9% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	20. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.3B
Vorheriger Eröffnungskurs	24.59
Vorheriger Schlusskurs	25.54

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

2.975 / 3.015 Unterstützung & Widerstand

Nanobiotix Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9. Apr. 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9. Apr. 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9. Apr. 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9. Apr. 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9. Apr. 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9. Apr. 2026, 22:31 UTC

Wichtige Nachrichtenereignisse

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9. Apr. 2026, 22:31 UTC

Wichtige Nachrichtenereignisse

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9. Apr. 2026, 20:57 UTC

Wichtige Nachrichtenereignisse

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9. Apr. 2026, 20:55 UTC

Ergebnisse

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Apr. 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Rowan Digital Infrastructure Announces Strategic Recapitalization

9. Apr. 2026, 20:25 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Apr. 2026, 19:30 UTC

Wichtige Nachrichtenereignisse

How Digital Currencies Have Helped Iran -- WSJ

Peer-Vergleich

Kursveränderung

Nanobiotix Prognose

Kursziel

By TipRanks

24.9% Vorteil

12-Monats-Prognose

Durchschnitt 32 EUR 24.9%

Hoch 32 EUR

Tief 32 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Nanobiotix – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Nanobiotix – Dist abgegeben haben.

Technischer Score

By Trading Central

2.975 / 3.015Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.